thalidomide has been researched along with Soft Tissue Neoplasms in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 9.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas." | 7.91 | Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019) |
| "Thalidomide is an antiangiogenic drug that produces a response rate ranging from 32 to 64% in patients with refractory/relapsed multiple myeloma (MM)." | 7.72 | Extramedullary multiple myeloma escapes the effect of thalidomide. ( Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 5.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas." | 3.91 | Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019) |
| "Thalidomide is an antiangiogenic drug that produces a response rate ranging from 32 to 64% in patients with refractory/relapsed multiple myeloma (MM)." | 3.72 | Extramedullary multiple myeloma escapes the effect of thalidomide. ( Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "Metastatic renal cell cancer is one of the immuno-sensitive tumors." | 2.71 | Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. ( Bex, A; Boogerd, W; de Gast, GC; Dewit, L; Haanen, JB; Kerst, JM; Mallo, H; Teertstra, HJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiménez-Segura, R | 1 |
| Granell, M | 1 |
| Gironella, M | 1 |
| Abella, E | 1 |
| García-Guiñón, A | 1 |
| Oriol, A | 1 |
| Cabezudo, E | 1 |
| Clapés, V | 1 |
| Soler, JA | 1 |
| Escoda, L | 1 |
| López-Pardo, J | 1 |
| Fernández de Larrea, C | 1 |
| Cibeira, MT | 2 |
| Tovar, N | 1 |
| Isola, I | 1 |
| Bladé, J | 2 |
| Rosiñol, L | 2 |
| Rezvani, H | 1 |
| Haghighi, S | 1 |
| Ghadyani, M | 1 |
| Attarian, H | 1 |
| González-Porras, JR | 1 |
| González, M | 1 |
| García-Sanz, R | 1 |
| San Miguel, JF | 1 |
| Pawlak, WZ | 1 |
| Legha, SS | 1 |
| Esteve, J | 1 |
| Aymerich, M | 1 |
| Rozman, M | 1 |
| Segarra, M | 1 |
| Cid, MC | 1 |
| Filella, X | 1 |
| Montserrat, E | 1 |
| Kerst, JM | 1 |
| Bex, A | 1 |
| Mallo, H | 1 |
| Dewit, L | 1 |
| Haanen, JB | 1 |
| Boogerd, W | 1 |
| Teertstra, HJ | 1 |
| de Gast, GC | 1 |
3 trials available for thalidomide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Fre | 2012 |
Phase II study of thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Humans; Lung Neoplasms; Male; Max | 2004 |
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; | 2005 |
3 other studies available for thalidomide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2019 |
Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clavicle; Cyclophosphamide; Dexamethasone; Dru | 2002 |
Extramedullary multiple myeloma escapes the effect of thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow Neoplasms; Dose-Response Relati | 2004 |